                         SEQUENCE LISTING

<110>  THE JOHNS HOPKINS UNIVERSITY
       FUCHS, Ephraim Joseph
       SYMONS, Heather Jill
       SWINNEN, Lode
 
<120>  Cancer Immunotherapy Using Transfusions Of Allogeneic, 
       Tumor-Specific CD4+ T Cells

<130>  JHU3680-3WO

<150>  US 16/786,761
<151>  2020-02-10

<160>  11    

<170>  PatentIn version 3.5

<210>  1
<211>  27
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  1

Pro Ser Lys Pro Ser Phe Gln Glu Phe Val Asp Trp Glu Lys Val Ser 
1               5                   10                  15      


Pro Glu Leu Asn Ser Thr Asp Gln Pro Phe Leu 
            20                  25          


<210>  2
<211>  27
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  2

Pro Ser Lys Pro Ser Phe Gln Glu Phe Val Asp Trp Glu Asn Val Ser 
1               5                   10                  15      


Pro Glu Leu Asn Ser Thr Asp Gln Pro Phe Leu 
            20                  25          


<210>  3
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  3

Ser Ile Ile Asn Phe Glu Lys Leu 
1               5               


<210>  4
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  4

Ile Ser Gln Ala Val His Ala Ala His Ala Glu Ile Asn Glu Ala Gly 
1               5                   10                  15      


Arg 
    


<210>  5
<211>  27
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  5

Pro Ser Lys Pro Ser Phe Gln Glu Phe Val Asp Trp Glu Lys Val Ser 
1               5                   10                  15      


Pro Glu Leu Asn Ser Thr Asp Gln Pro Phe Leu 
            20                  25          


<210>  6
<211>  27
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  6

Pro Ser Lys Pro Ser Phe Gln Glu Phe Val Asp Trp Glu Asn Val Ser 
1               5                   10                  15      


Pro Glu Leu Asn Ser Thr Asp Gln Pro Phe Leu 
            20                  25          


<210>  7
<211>  98
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  7

Met His Gly Asp Thr Pro Thr Leu His Glu Tyr Met Leu Asp Leu Gln 
1               5                   10                  15      


Pro Glu Thr Thr Asp Leu Tyr Cys Tyr Glu Gln Leu Asn Asp Ser Ser 
            20                  25                  30          


Glu Glu Glu Asp Glu Ile Asp Gly Pro Ala Gly Gln Ala Glu Pro Asp 
        35                  40                  45              


Arg Ala His Tyr Asn Ile Val Thr Phe Cys Cys Lys Cys Asp Ser Thr 
    50                  55                  60                  


Leu Arg Leu Cys Val Gln Ser Thr His Val Asp Ile Arg Thr Leu Glu 
65                  70                  75                  80  


Asp Leu Leu Met Gly Thr Leu Gly Ile Val Cys Pro Ile Cys Ser Gln 
                85                  90                  95      


Lys Pro 
        


<210>  8
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  8

Met His Gly Asp Thr Pro Thr Leu His Glu Tyr Met Leu Asp Leu 
1               5                   10                  15  


<210>  9
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  9

Thr Pro Thr Leu His Glu Tyr Met Leu Asp Leu Gln Pro Glu Thr 
1               5                   10                  15  


<210>  10
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  10

His Glu Tyr Met Leu Asp Leu Gln Pro Glu Thr Thr Asp Leu Tyr 
1               5                   10                  15  


<210>  11
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  11

Leu Asp Leu Gln Pro Glu Thr Thr Asp Leu Tyr Cys Tyr Glu Gln 
1               5                   10                  15  


